10-Q: Vaso Corporation Reports Slight Revenue Increase in Q1 2025, Operating Loss Improves

Vaso Corporation's Q1 2025 shows a modest revenue increase and an improved operating loss compared to the same period last year.

Summary

• Vaso Corporation reported total revenue of $19.462 million for the three months ended March 31, 2025, compared to $18.738 million for the same period in 2024, representing a 4% increase.
• The professional sales service segment and IT segment saw revenue increases of $578,000 and $162,000, respectively, while the equipment segment experienced a $16,000 decrease.
• The IT segment's revenue was $10.315 million, a 2% increase, driven by higher NetWolves revenue, partially offset by lower healthcare IT revenue.
• Commission revenues in the professional sales service segment increased by 7% to $8.705 million due to higher deliveries by GEHC, offset by a lower blended commission rate.
• The equipment segment's revenue decreased by 3% to $442,000, primarily due to lower deliveries in China, partially offset by higher ARCS-cloud revenues in the US.
• Gross profit increased by 4% to $11.358 million, with the professional sales service segment showing the largest increase.
• Operating loss improved to $1.218 million from $1.468 million, driven by higher gross profit and lower business combination transaction costs, partially offset by higher SG&A expenses.
• The IT segment's operating loss increased to $798,000, while the professional sales service segment recorded an operating income of $347,000.
• The equipment segment's operating loss improved to $246,000.
• Adjusted EBITDA increased by $151,000 to ($1,115,000).
• Net loss decreased to $1.075 million from $1.173 million, with a loss per share of $0.01 in both periods.
• Cash and cash equivalents were $25.311 million at March 31, 2025, compared to $26.271 million at December 31, 2024.
• Working capital was $15.736 million at March 31, 2025, compared to $16.465 million at December 31, 2024.

Sentiment

Score: 5

Explanation: The report presents mixed results, with revenue growth offset by increased operating losses in some segments and an overall net loss. The sentiment is neutral, reflecting both positive and negative aspects of the company's performance.

Positives

• Total revenue increased by 4% year-over-year.
• Operating loss improved by $250,000.
• Adjusted EBITDA increased by $151,000.
• The professional sales service segment recorded an operating income of $347,000, compared to an operating loss of $7,000 in the same period last year.

Negatives

• The IT segment's operating loss increased by $378,000.
• The equipment segment experienced a 3% decrease in revenue.
• Cash and cash equivalents decreased from $26.271 million to $25.311 million.
• Net loss was $1.075 million.

Risks

• The company's performance is subject to business and economic conditions, including potential downturns in the U.S. economy.
• US tariff policies could impact the company's operations.
• Changes in IT and healthcare industries could affect the company's business.
• The continuation of the GEHC agreement is critical to the company's professional sales service segment.
• Competitive technology and products and their pricing pose a risk.
• Medical insurance reimbursement policies could impact the company's revenue.
• Unexpected manufacturing or supplier problems could disrupt operations.
• Unforeseen difficulties and delays in product development programs could affect the company's growth.
• Actions of regulatory authorities and third-party payers could impact the company's business.
• Increased government scrutiny of healthcare purchasing practices in China could affect the equipment segment.

Future Outlook

Vaso intends to continue to seek opportunities to increase stockholder value, including through internal growth, new partnerships and strategic investments with a concentration on medical and IT service companies.

Management Comments

• Vaso intends to continue to seek opportunities to increase stockholder value, including through internal growth, new partnerships and strategic investments with a concentration on medical and IT service companies.

Industry Context

The report indicates Vaso Corporation operates in the healthcare equipment and information technology industries, facing competition and evolving market dynamics.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• Without further information, it is difficult to assess Vaso Corporation's performance relative to its peers or industry averages.

Legal Proceedings

• The Company is currently, and has been in the past, a party to various legal proceedings, primarily employee-related matters, incident to its business.
• The Company believes that the outcome of all pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.

Related Party Transactions

• For the three months ended March 31, 2025 and 2024, the Company's share of EECP Global's loss was approximately $68,000 and $31,000, respectively, and was included in Other (Expense) Income in its condensed consolidated statements of operations.
• At March 31, 2025 and December 31, 2024, the Company recorded a net receivable from related parties of approximately $1,064,000 and $916,000, respectively, on its condensed consolidated balance sheets for amounts due from EECP Global for fees and cost reimbursements net of amounts due to EECP Global for receivables collected on its behalf.

Stakeholder Impact

• The company's performance impacts shareholders through stock value and potential dividends.
• Employees are affected by the company's financial stability and growth prospects.
• Customers rely on the company's products and services.
• Suppliers and creditors are impacted by the company's ability to meet its obligations.

Next Steps

• Vaso intends to continue to seek opportunities to increase stockholder value, including through internal growth, new partnerships and strategic investments with a concentration on medical and IT service companies.

Key Dates

Keywords

Vaso Corporation, financial results, Q1 2025, revenue, operating loss, IT segment, professional sales service, equipment segment, GEHC, Adjusted EBITDA